ADDV-B.ST
ADDvise Group AB (publ) [ADDV-B.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ADDV-B.ST Stock Summary
Top 10 Correlated ETFs
ADDV-B.ST
Top 10 Correlated Stocks
ADDV-B.ST
In the News
ADDV-B.ST Financial details
Company Rating
Strong Buy
Market Cap
1.56B
Income
103.5M
Revenue
1.37B
Book val./share
3.26
Cash/share
2.05
Dividend
-
Dividend %
-
Employees
624
Optionable
No
Shortable
Yes
Earnings
18 Apr 2024
P/E
24.62
Forward P/E
-
PEG
11.65
P/S
2.1
P/B
3.51
P/C
3.43
P/FCF
20.83
Quick Ratio
1.3
Current Ratio
2.12
Debt / Equity
2.52
LT Debt / Equity
2.38
-
-
EPS (TTM)
0.56
EPS next Y
-
EPS next Q
-
EPS this Y
21.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
66.02%
Revenue last 5Y
31.45%
Revenue Q/Q
23.64%
EPS Q/Q
-11.11%
-
-
-
-
SMA20
-11.11%
SMA50
-42.86%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
17%
ROC
0.14%
Gross Margin
65%
Oper. Margin
22%
Profit Margin
8%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.13-16.86
52W High
-56%
52W Low
+0.57%
RSI
22
Rel Volume
6.01
Avg Volume
618.65K
Volume
3.72M
Perf Week
-10.89%
Perf Month
-28.96%
Perf Quarter
-15.18%
Perf Half Y
-7%
-
-
-
-
Beta
0.401
-
-
Volatility
0.36%, 0.77%
Prev Close
-12.22%
Price
7.04
Change
-12.33%
ADDV-B.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.82 | 3.7 | 3.26 | 5.36 | 7.39 | |
| Net income per share | 0.04 | 0.15 | 0.02 | 0.46 | 0.56 | |
| Operating cash flow per share | 0.12 | 0.59 | 0.07 | 0.62 | 0.94 | |
| Free cash flow per share | 0.06 | 0.58 | 0.04 | 0.54 | 0.83 | |
| Cash per share | 0.14 | 0.41 | 2.18 | 0.55 | 2.08 | |
| Book value per share | 0.92 | 0.94 | 1.73 | 2.78 | 3.3 | |
| Tangible book value per share | -1.34 | -1.11 | -1.35 | -4.45 | -8.72 | |
| Share holders equity per share | 0.92 | 0.94 | 1.73 | 2.78 | 3.3 | |
| Interest debt per share | 2.29 | 2.13 | 4.13 | 4.64 | 8.84 | |
| Market cap | 67.7M | 124.05M | 1.26B | 1.31B | 2.45B | |
| Enterprise value | 250.49M | 277.82M | 1.49B | 1.98B | 3.67B | |
| P/E ratio | 16.68 | 8.47 | 449.05 | 16.19 | 23.62 | |
| Price to sales ratio | 0.19 | 0.35 | 2.7 | 1.38 | 1.78 | |
| POCF ratio | 6.05 | 2.16 | 123.66 | 11.95 | 13.98 | |
| PFCF ratio | 12.64 | 2.22 | 208.23 | 13.69 | 15.77 | |
| P/B Ratio | 0.81 | 1.36 | 5.09 | 2.66 | 3.99 | |
| PTB ratio | 0.81 | 1.36 | 5.09 | 2.66 | 3.99 | |
| EV to sales | 0.72 | 0.77 | 3.19 | 2.08 | 2.67 | |
| Enterprise value over EBITDA | 9.24 | 6.51 | 25.31 | 10.9 | 9.09 | |
| EV to operating cash flow | 22.39 | 4.84 | 146.09 | 18.02 | 21 | |
| EV to free cash flow | 46.78 | 4.97 | 246 | 20.64 | 23.68 | |
| Earnings yield | 0.06 | 0.12 | 0 | 0.06 | 0.04 | |
| Free cash flow yield | 0.08 | 0.45 | 0 | 0.07 | 0.06 | |
| Debt to equity | 2.33 | 2.13 | 2.24 | 1.58 | 2.52 | |
| Debt to assets | 0.54 | 0.56 | 0.52 | 0.4 | 0.47 | |
| Net debt to EBITDA | 6.75 | 3.61 | 3.89 | 3.67 | 3.04 | |
| Current ratio | 0.99 | 1.11 | 3.15 | 1.36 | 1.19 | |
| Interest coverage | 1.35 | 2.66 | 1.16 | 3.44 | 3.12 | |
| Income quality | 6.69 | 3.22 | 1.33 | 1.02 | 1.69 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 1 | 0 | 0 | |
| Sales general and administrative to revenue | 0.09 | 0.08 | 0.1 | 0.19 | 0 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Intangibles to total assets | 0.57 | 0.57 | 0.41 | 0.65 | 0.68 | |
| Capex to operating cash flow | -0.52 | -0.03 | -0.41 | -0.13 | -0.11 | |
| Capex to revenue | -0.02 | 0 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.64 | -0.18 | -0.39 | -0.5 | -0.19 | |
| Stock based compensation to revenue | 0 | -0.06 | 0 | 0 | 0 | |
| Graham number | 0.96 | 1.79 | 0.87 | 5.34 | 6.43 | |
| ROIC | 0.15 | 0.09 | 0.02 | 0.09 | 0.09 | |
| Return on tangible assets | 0.03 | 0.1 | 0 | 0.12 | 0.1 | |
| Graham Net | -2.08 | -1.67 | -2.55 | -6.07 | -10.77 | |
| Working capital | -908K | 11.89M | 374.78M | 145.5M | 133.5M | |
| Tangible asset value | -122.88M | -107.35M | -193.67M | -789.27M | -1.62B | |
| Net current asset value | -150.96M | -130.55M | -273.09M | -930.75M | -1.85B | |
| Invested capital | 2.33 | 2.13 | 2.24 | 1.58 | 2.52 | |
| Average receivables | 36.2M | 60.72M | 99.4M | 240.65M | 316.42M | |
| Average payables | 29.52M | 30.98M | 44.7M | 87.25M | 107.39M | |
| Average inventory | 36.51M | 35.34M | 49.98M | 84.54M | 111.87M | |
| Days sales outstanding | 75.54 | 49.93 | 117.32 | 127.18 | 80.1 | |
| Days payables outstanding | 56.33 | 48.15 | 88.3 | 110.68 | 34.24 | |
| Days of inventory on hand | 63.8 | 55.35 | 97.39 | 99.4 | 41.25 | |
| Receivables turnover | 4.83 | 7.31 | 3.11 | 2.87 | 4.56 | |
| Payables turnover | 6.48 | 7.58 | 4.13 | 3.3 | 10.66 | |
| Inventory turnover | 5.72 | 6.59 | 3.75 | 3.67 | 8.85 | |
| ROE | 0.05 | 0.16 | 0.01 | 0.16 | 0.17 | |
| Capex per share | -0.06 | -0.02 | -0.03 | -0.08 | -0.11 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.8 | 1.72 | 1.85 | 1.71 | 2.11 | |
| Net income per share | 0.16 | 0.2 | 0.02 | 0.18 | 0.16 | |
| Operating cash flow per share | 0.57 | 0.57 | -0.06 | 0.17 | 0.27 | |
| Free cash flow per share | 0.53 | 0.55 | -0.06 | 0.13 | 0.23 | |
| Cash per share | 0.55 | 1.04 | 3.14 | 2.98 | 2.05 | |
| Book value per share | 2.78 | 2.94 | 3.66 | 3.73 | 3.26 | |
| Tangible book value per share | -4.45 | -4.21 | -3.54 | -3.32 | -8.61 | |
| Share holders equity per share | 2.78 | 2.94 | 3.66 | 3.73 | 3.26 | |
| Interest debt per share | 4.56 | 4.23 | 6.41 | 6.04 | 8.49 | |
| Market cap | 1.31B | 2.19B | 2.67B | 1.67B | 2.48B | |
| Enterprise value | 1.98B | 2.79B | 3.21B | 2.22B | 3.7B | |
| P/E ratio | 11.69 | 15.41 | 208.94 | 12 | 20.71 | |
| Price to sales ratio | 4.1 | 7.07 | 7.77 | 5.2 | 6.24 | |
| POCF ratio | 12.89 | 21.41 | -249.94 | 52.88 | 48.09 | |
| PFCF ratio | 13.97 | 22.21 | -236.67 | 68.49 | 57.33 | |
| P/B Ratio | 2.66 | 4.14 | 3.93 | 2.38 | 4.04 | |
| PTB ratio | 2.66 | 4.14 | 3.93 | 2.38 | 4.04 | |
| EV to sales | 6.18 | 8.99 | 9.32 | 6.92 | 9.33 | |
| Enterprise value over EBITDA | 22.78 | 33.15 | 26.39 | 23.76 | 34.58 | |
| EV to operating cash flow | 19.43 | 27.23 | -299.9 | 70.31 | 71.91 | |
| EV to free cash flow | 21.07 | 28.25 | -283.97 | 91.06 | 85.73 | |
| Earnings yield | 0.02 | 0.02 | 0 | 0.02 | 0.01 | |
| Free cash flow yield | 0.07 | 0.05 | 0 | 0.01 | 0.02 | |
| Debt to equity | 1.58 | 1.39 | 1.66 | 1.6 | 2.52 | |
| Debt to assets | 0.4 | 0.38 | 0.45 | 0.47 | 0.47 | |
| Net debt to EBITDA | 7.67 | 7.08 | 4.4 | 5.89 | 11.46 | |
| Current ratio | 1.36 | 1.21 | 2 | 2.12 | 1.19 | |
| Interest coverage | 2.56 | 2.82 | 1.4 | 4.3 | 1.49 | |
| Income quality | 2.27 | 2.88 | -0.43 | 0.62 | 1.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.18 | 0 | 0.15 | 0 | 0 | |
| Research and developement to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.65 | 0.66 | 0.53 | 0.56 | 0.68 | |
| Capex to operating cash flow | -0.08 | -0.04 | 0.06 | -0.23 | -0.16 | |
| Capex to revenue | -0.02 | -0.01 | 0 | -0.02 | -0.02 | |
| Capex to depreciation | -0.72 | -0.24 | -0.02 | -0.27 | -0.26 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.14 | 3.61 | 1.19 | 3.94 | 3.41 | |
| ROIC | 0.04 | 0.04 | 0.01 | 0.02 | 0.02 | |
| Return on tangible assets | 0.04 | 0.05 | 0 | 0.03 | 0.03 | |
| Graham Net | -6.07 | -5.56 | -5.11 | -4.65 | -10.63 | |
| Working capital | 145.5M | 90.6M | 507.1M | 492.7M | 133.5M | |
| Tangible asset value | -789.27M | -759.5M | -659.6M | -624.4M | -1.62B | |
| Net current asset value | -930.75M | -895.4M | -810.1M | -751M | -1.85B | |
| Invested capital | 1.58 | 1.39 | 1.66 | 1.6 | 2.52 | |
| Average receivables | 290.92M | 291.52M | 283.9M | 291.5M | 284M | |
| Average payables | 103.1M | 94.29M | 76.45M | 96.45M | 107.5M | |
| Average inventory | 108.44M | 97.07M | 96.75M | 98.8M | 108.45M | |
| Days sales outstanding | 93.17 | 72.9 | 82.66 | 74.75 | 68.3 | |
| Days payables outstanding | 92.56 | 27.73 | 64.94 | 93.35 | 28.18 | |
| Days of inventory on hand | 83.13 | 34.14 | 84.29 | 78.09 | 33.95 | |
| Receivables turnover | 0.97 | 1.23 | 1.09 | 1.2 | 1.32 | |
| Payables turnover | 0.97 | 3.25 | 1.39 | 0.96 | 3.19 | |
| Inventory turnover | 1.08 | 2.64 | 1.07 | 1.15 | 2.65 | |
| ROE | 0.06 | 0.07 | 0 | 0.05 | 0.05 | |
| Capex per share | -0.04 | -0.02 | 0 | -0.04 | -0.04 |
ADDV-B.ST Frequently Asked Questions
What is ADDvise Group AB (publ) stock symbol ?
ADDvise Group AB (publ) is a SE stock and trading under the symbol ADDV-B.ST
What is ADDvise Group AB (publ) stock quote today ?
ADDvise Group AB (publ) stock price is $7.04 today.
Is ADDvise Group AB (publ) stock public?
Yes, ADDvise Group AB (publ) is a publicly traded company.
Company Profile
- Volume Average 618.65K
- Market Capitalization 1.56B
- Employee 624
- CEO Mr. Richard Akhtarzand
- Headquarters Stockholm,SE
- IPO Date 2015-09-14
-
Website
https://www.addvisegroup.se 
ADDvise Group AB (publ) supplies equipment to healthcare and research facilities in private and public sectors in Sweden, rest of Europe, North America, Africa, and Asia. The company's Lab business unit designs, manufactures, and sells clean room systems and safety ventilation to laboratories, and scales to the research, industrial and grocery sectors. It is also involved in sale of equipment to laboratories, including centrifuges, water baths, and environmental chambers, and service and maintenance of scales, laboratory equipment, and storage of products. Its Healthcare business unit engages in the design, manufacture, and sale of the surgical tables, healthcare, and safety products, medtech cables, connection systems, orthopedic implants, stents for foot and ankle surgery, equipment, and software for monitoring patients, as well as operates online pharmacy. This segment also offers sale of consumable materials for healthcare, ultrasound systems, radiographic equipment, and examination tables for urology and gynecology. In addition, the company supplies laboratory furnishings and apparatus. ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.
